Study explainer
After treatment stops: what weight-regain research tells us.
A 2026 review explores the pattern of regain — and why a model is not an individual prediction.
Behind the headlines.
Short, sourced reports on studies and regulator updates. With the question, the finding and the limitations kept together.
Regulator update
A tablet approval is only one part of the access story.
What the MHRA announcement on oral semaglutide establishes, and what it does not.
Safety update
Understanding the updated pancreatitis warning.
The MHRA strengthened product information. Here is the context behind that update.
Published 16 September 2026. Study and announcement dates are shown on each card. Source summaries are not independently clinically reviewed.